NRXP
NRX Pharmaceuticals Inc
3.00$
-1.2%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | 100.0% | |
| – | – | – | – | – | – | – | – | 41.2% | |
| – | – | – | – | – | – | – | – | 58.8% | |
| – | – | – | – | – | – | – | – | 308.3% | |
| – | – | – | – | – | – | – | – | 1,066.2% | |
| – | – | – | – | – | – | – | – | 1,383.2% | |
| – | – | – | – | – | – | – | – | -1,324.4% | |
| – | – | – | – | – | – | – | – | 54.8% | |
| – | – | – | – | – | – | – | – | -2,336.5% | |
| – | – | – | – | – | – | – | – | -2,336.5% | |
| – | – | – | – | – | – | – | – | -2,270.0% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.